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Summary
Insulin resistance is thought to be the primary defect in
the pathophysiology of type 2 diabetes. Thus, under-
standing the cellular mechanisms of insulin action may
contribute significantly to developing new treatments for
this disease. Although the effects of insulin on glucose
and lipid metabolism are well documented, gaps remain
in our understanding of the precise molecular mechan-
isms of signal transduction for the hormone. One
potential clue to understanding the unique cellular
effects of insulin may lie in the compartmentalization of
signaling molecules and metabolic enzymes. We review
this evidence, and speculate on how PI-3 kinase-inde-
pendent and -dependent signaling pathways both di-
verge from the insulin receptor and converge at discrete
targets to insure the specificity of insulin action. BioEs-
says 23:215±222, 2001. ß 2001 John Wiley & Sons, Inc.
Introduction
Diabetes mellitus is a worldwide epidemic, in some ethnic
groups affecting over 10% of the population. Type 1 diabetes,
defined by an absolute requirement for administration of
exogenous insulin, results from the autoimmune destruction of
the insulin-secreting pancreatic b cells. Type 2 diabetes
usually occurs during adulthood, and is often characterized
by a relative resistance to endogenous insulin. The pathophy-
siology of type 2 diabetes, which accounts for over 90% of
patients with the disease, involves defects in three organ
systems that conspire together to produce abnormal glucose
and lipid metabolism. While there is some uncertainty
regarding the primary lesion, or relative importance of different
tissues, metabolic defects in liver, peripheral target tissues
such as fat and muscle and pancreatic b cells all contribute to
the syndrome. Insulin resistance, which is defined as a state of
reduced responsiveness to normal circulating concentrations
of insulin, is now recognized as a characteristic trait of type 2
diabetes, and contributes to abnormalities in all of these
tissues.
A number of prospective epidemiological studies across
several population groups have indicated that type 2 diabetes
progresses over a continuum of worsening insulin action,
beginning with peripheral insulin resistance and ending with a
loss of insulin secretion. In most patients, insulin resistance
can be detected long before the deterioration of glucose
intolerance occurs. Insulin resistance is a quite common state,
associated with aging, a sedentary lifestyle, as well as a
genetic predisposition. The state seems to be fueled by or
perhaps to a certain extent the result of obesity. The ensuing
dysregulation of carbohydrate and lipid metabolism that
occurs as a consequence of insulin resistance further exacer-
bates its progression. Beta cells of the pancreas normally
compensate for the insulin-resistant state by increasing basal
and postprandial insulin secretion. At some point, the beta
cells can no longer compensate, failing to respond appro-
priately to glucose. This ultimately leads to the deterioration of
glucose homeostasis, and the development of glucose into-
lerance. Approximately 5±10% of glucose intolerant patients
per year progress to frank diabetes, which continues to worsen
as insulin resistance increases. Adipose cells generate more
fatty acids, the liver produces more glucose in an unregulated
fashion, and the beta cells undergo complete failure, resulting
in the late stages of the disease, where high doses of
exogenous insulin may be required.
Even in the absence of diabetes, insulin resistance is a key
feature of other human disease states. Impaired insulin action
coupled with hyperinsulinemia leads to a variety of abnorm-
alities, including elevated triglycerides, low levels of HDL,
enhanced secretion of VLDL, disorders of coagulation,
increased vascular resistance, changes in steroid hormone
levels, attenuation of peripheral blood flow and weight gain.
Thus, insulin resistance is often associated with central
obesity, hypertension, polycystic ovarian syndrome, dyslipi-
demia and atherosclerosis. This constellation of symptoms is
often referred to as Syndrome X, or Insulin Resistance
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Syndrome. Whether impaired insulin action is directly respon-
sible for all of the symptoms in these patients remains unclear.
However, the broad prevalence of insulin resistance, and its
association with profound metabolic abnormalities is widely
accepted.
Insulin is the most potent anabolic agent known, promoting
the synthesis and storage of carbohydrates, lipids and
proteins, and inhibiting their degradation and release back
into the circulation. Insulin maintains glucose homeostasis by
stimulating glucose uptake, utilization and storage in muscle
and adipose tissue, and inhibiting glucose output from liver.
The hormone also plays an important role in regulating lipid
homeostasis, stimulating lipogenesis in fat and liver, and
inhibiting lipolysis in fat and muscle. While the underlying
cause of insulin resistance remains unknown, investigations
have focused on defects in signaling and metabolic pathways.
Studies in type 2 diabetic patients have shown that the primary
defect in insulin action lies in the regulation of glucose
transport in adipose and muscle. This process is mediated
by the insulin-stimulated glucose transporter, Glut4.(1)
Insulin action is initiated through the binding to and
activation of its tyrosine kinase receptor. At the cellular level,
the action of the hormone is characterized by a diverse variety
of effects, including changes in vesicle trafficking, stimulation
of protein kinases and phosphatases, promotion of cellular
growth and differentiation, and activation, or in some cases,
repression of transcription. The diverse mechanisms involved
in these varied downstream effects suggest that insulin action
must involve multiple signaling pathways that diverge at or
near the receptor. In this regard, the receptor catalyzes the
phosphorylation of several substrates, including the insulin
receptor substrate (IRS) proteins,(2) GAB-1,(3,4) Shc(5) and c-
Cbl(6) (see Fig. 1). Each of these substrates recruits a distinct
subset of signaling protein containing SH2 domains, in a
phosphotyrosine-dependent manner.(2,7,8) Once phosphory-
lated, the substrate Shc interacts with the adapter protein
Grb2, leading to activation of the Ras/Raf/Map kinase path-
way.(9) GAB-1 phosphorylation also plays a role in MAP
kinase activation, via the tyrosine phosphatase SHP-2.(10±12)
Although there are multiple pathways for the activation of MAP
kinase, the enzyme is similarly activated by other growth
factors that are not insulinomimetic, and is neither necessary
nor sufficient for the metabolic actions of insulin.(13,14)
Most attention in the field of insulin receptor substrates has
focused on the IRS family of proteins. The tyrosine phospho-
rylation of IRS proteins generates docking sites for a number
of SH2-containing proteins.(2) The predominant partner,
however, seems to be the p85 regulatory subunit of the type
1A PI 3-kinase.(15) PI 3-kinase catalyzes the formation of
phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3), which
Figure 1. The insulin receptor tyrosine kinase substrates and downstream signaling pathways. Upon insulin binding, the insulin
receptor undergoes autophosphorylation on tyrosine residues within the b-chain of the receptor, recruiting substrate proteins (IRS1-4,
Gab1 and Shc) that are tyrosine phosphorylated. Phosphorylation of c-Cbl requires the adapter protein CAP for the recruitment to the
insulin receptor. Once phosphorylated, these substrates engage a variety of effector proteins via SH2 domain interactions, including the
tyrosine phosphatase SHP2, the adapters crk and Grb2 and the p85 regulatory subunit of PI 3-kinase. Activation or localization of these
proteins initiates multiple signaling pathways that regulate diverse functions including metabolic activity, growth and differentiation.
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serves as an allosteric regulator of the phosphoinositide-
dependent kinase (PDK).(16) PDK can in turn phosphorylate
and activate protein kinase B (PKB/Akt) as well as the atypical
protein kinase C isoforms PKCz and PKCl.(16,17)
Although there is substantial controversy regarding the
potential roles of either PKB/Akt or PKCz/l in insulin-
stimulated Glut4 translocation, PI 3-kinase appears to be
essential. Inhibition of PI 3-kinase activity with pharmacologi-
cal inhibitors such as wortmannin, expression of dominant-
interfering mutants, or microinjection of blocking antibodies
can completely prevent the stimulation of glucose uptake and
Glut4 translocation by insulin.(18±20) Although these data
demonstrate the necessity of PI 3-kinase, several lines of
evidence indicate that activation of the enzyme is not
sufficient. Dramatic overexpression of constitutively active
mutants of PI 3-kinase can stimulate Glut4 translocation only
partially.(21) Other growth factors, such as PDGF and IL-4, or
certain adhesion molecules, stimulate PI 3-kinase to an extent
similar to that seen with insulin, but have only a minor effect on
glucose uptake and Glut4 translocation.(22,23) In addition, cell-
permeable derivatives of PI-3,4,5-P3 alone cannot mimic the
stimulation of glucose uptake by insulin, but can stimulate
when cells are pretreated with insulin and a pharmacological
inhibitor of PI 3-kinase.(24) Furthermore, several studies have
demonstrated that exercise, contraction and hypoxia can all
induce glucose uptake and Glut4 translocation in skeletal
muscle independent of any detectable PI 3-kinase activa-
tion.(25,26) Taken together, these data suggest that insulin
must generate at least two independent signals to stimulate
glucose transport, one dependent on and another indepen-
dent of PI 3-kinase. Moreover, the activation of PI 3-kinase by
noninsulinomimetic hormones suggests that the second
pathway must be unique for insulin. In this review, we will
discuss the search for a second signaling pathway, and the
potential role of spatial compartmentalization in the specificity
of signal transduction in insulin action, particularly regarding
the stimulation of glucose transport.
Glucose transport and Glut4
In mammalian tissues, insulin-stimulated glucose uptake is
mediated by the facilitative transporter Glut4, a member of a
family of related integral-membrane proteins.(27) Glut4 is
highly expressed in skeletal and cardiac muscle and adipose
tissue. In the basal state, Glut4 slowly recycles between the
plasma membrane and vesicular compartments within the cell,
where most of the Glut4 resides. Upon insulin stimulation,
Glut4 rapidly translocates to the plasma membrane, through a
process of targeted exocytosis. At the same time, Glut4
endocytosis is attenuated, resulting in a dramatic increase in
glucose uptake.(28)
Although there is substantial evidence that Glut4 exists in
specialized vesicles sequestered within the cell, the precise
intracellular location and trafficking pathways of these vesicles
are unclear. Immunoelectron microscopy has demonstrated
the predominant localization of Glut4 in tubulovesicular and
vesicular structures, with the some of the protein localized to
clathrin-coated vesicles, endosomal structures and the trans-
Golgi network.(28) The Glut4 vesicle appears to be biochemi-
cally distinct from the vesicles of the recycling endosomal
network, which contain the Glut1 transporter as well as the
transferrin and mannose 6-phosphate receptors.(29) Further-
more, the Glut4 compartment is enriched in the v-SNARE
(soluble N-ethylmaleimide sensitive factor attachment protein)
protein VAMP2 but not the related VAMP3/cellubrevin isoform
that is present in the recycling endosome.(28)
This specific compartmentalization of Glut4 provides a
mechanism by which insulin can stimulate robust translocation
of Glut4 to the plasma membrane, while only mildly stimulating
the translocation of recycling proteins (Fig. 2). Although the
mechanism of intracellular tethering of the Glut4 vesicle in
resting cells is unknown, sequestration of Glut4 is dependent
on C-terminal sequences in the protein.(30±33) The Glut4
compartment also contains the insulin-responsive aminopep-
tidase (IRAP).(34,35) Overexpression of the N terminus of
IRAP, which has significant homology to the C terminus of
Glut4, results in Glut4 localization to the plasma membrane.
These results suggest that both the C terminus of Glut4 and
the N terminus of IRAP contribute to the cytoplasmic
sequestration of Glut4 vesicle. However, the cytoplasmic
targets of IRAP and Glut4 are unknown. One potential site for
Glut4 tethering is the actin cytoskeleton. Insulin stimulates
cytoskeletal rearrangement, possibly through the activation of
proteins known to regulate actin polymerization, such as
effectors of the Rho family of small G-proteins.(36) In this
regard, depolymerization of the actin cytoskeleton potently
inhibits Glut4 translocation.(37,38) Interestingly, the C-terminal
domain of Glut4 can interact with the glycolytic enzyme
aldolase.(39) Aldolase can also bind to actin, and substrates of
aldolase can mediate the dissociation of the Glut4±aldolase
complex, potentially providing a negative feedback signal for
glucose transport. Thus aldolase may mediate the interaction
between Glut4 and the cytoskeleton.
Substantial evidence suggests that the plasma membrane
target for the GLUT4 vesicle is the t-SNARE, syntaxin 4
(Syn4).(40±43) Thus, the docking of the vesicle may be
mediated by the interaction of Syn4 with the Glut4 vesicle v-
SNARE protein, VAMP2. This interaction is reminiscent of the
v-SNARE/t-SNARE interaction seen in synaptic vesicle exo-
cytosis, suggesting that Glut4 exocytosis may occur through
mechanisms similar to those proposed for synaptic vesicle
transport.(44,45) Several proteins have been demonstrated to
bind to Syn4, including SNAP23,(43,46) Munc18c(47,48) and,
more recently, Synip,(49) to regulate the docking and fusion of
VAMP2-containing GLUT4 vesicles. Among these, Synip has
been shown to undergo an insulin-dependent release from
Syn4, allowing VAMP2 to bind to the protein.(49)
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Compartmentalized PI 3-kinase activation in the
regulation of Glut4 translocation by insulin
As mentioned above, it is likely that at least two signaling
pathways are required for the stimulation of Glut4 transloca-
tion in response to insulin. PI 3-kinase and its downstream
effectors are a necessary component of insulin-stimulated
Glut4 translocation. Pharmacological inhibitors of PI 3-kinase,
such as wortmannin,(18) or microinjection of dominant inter-
fering constructs containing the p85 regulatory subunit of PI 3-
kinase,(20) block insulin-stimulated Glut4 translocation. More-
over, microinjection of the inositol phosphatase SHIP2 that
specifically removes the phosphate from PIP3 blocks insulin
action.(50) Overexpression of PI 3-kinase or its downstream
targets Akt and PKC z/l in cell culture models increased
glucose uptake independent of insulin.(21,51±56) Moreover, in a
recent study of type 2 diabetic patients, PI 3-kinase activation
was impaired compared to normal subjects.(57)
Further evidence for an important role for PI 3-kinase has
emerged from studies on the IRS proteins. Mutation of the
insulin receptor at tyrosine 960, the docking site of IRS
proteins, abolishes insulin-stimulated glucose transport.(58)
Mice lacking the IRS-1 protein are insulin resistant, but do not
develop diabetes unless crossed to mice in which another
signaling molecule has been disrupted.(59±63) Animals lacking
IRS-2 exhibit both impaired glucose uptake and diabetes.(64)
However, the diabetic phenotype results from a defect in
insulin secretion as well as insulin resistance. The mechanism
of PI 3-kinase activation via IRS is distinct from that of other
tyrosine kinase receptors, such as PDGF and EGF, which
recruit PI 3-kinase directly to their receptors. This suggests
that the IRS proteins uniquely activate PI 3-kinase via
the recruitment of the enzyme to specific sites at or distal
to the plasma membrane, perhaps to intracellular mem-
branes.(22,65±67)
The formation of PIP3 by PI 3-kinase leads to the activation
of a number of protein kinases. PIP3 appears to mediate the
translocation of Akt to the plasma membrane, via its pleckstrin
homology (PH) domain.(68) PKCz/l- and phosphoinositide-
dependent kinase 1 (PDK1) translocate to the plasma
membrane by this same mechanism. Once at the plasma
membrane, Akt and PKCz/l are phosphorylated and activated
by PDK1. Although there are data to support an essential role
for these kinases in glucose transport, the precise identity of
the physiologically relevant kinase remains uncertain.(54,57)
Figure 2. Insulin stimulates glucose transport through PI 3-kinase-dependent and -independent signals that regulate GLUT4-
containing vesicles. The Glut4 transporter is retained in a specific intracellular vesicle compartment. These Glut4 vesicles (GSV) also
contain the v-SNARE protein VAMP2. Insulin causes the release of the GSV from intracellular tethering sites through an unknown
pathway initiated by the activation of PI 3-kinase. The docking and fusion of the GSV to the plasma membrane is subsequently mediated
through the interaction of the t-SNARE protein syntaxin4 (Syn4) with VAMP2. Other accessory proteins including SNAP23, Munc18c
and Synip regulate this docking and fusion process. Evidence suggests that insulin may also regulate that docking and fusion step
through the generation of PI3-kinase-independent signals.
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Also uncertain is whether these protein kinases migrate to new
sites upon activation, or whether there is local activation that
impacts on Glut4 translocation. Moreover, as of yet, there is no
information regarding the protein substrates that might be
involved in Glut4 translocation, although there is speculation
that this phosphorylation event might regulate the release of
the vesicle from intracellular tethering sites.
Other downstream effectors of PIP3 formation have also
been implicated in glucose transport. A class of proteins,
including GRP1/ARNO, which contain PH domains and Sec7
guanine nucleotide exchange domains for ARF proteins, are
recruited to the plasma membrane after insulin stimulation.(69±
72) The ARF proteins are involved in vesicle movement and
may be involved in insulin-stimulated membrane ruffling.
Recently, one downstream target of ARF, phospholipase D,
was demonstrated to colocalize with the Glut4 vesicle and to
potentiate the effects of insulin on Glut4 translocation.(73) It
remains unclear, however, whether insulin regulates the
activity of phospholipase D. One other potential target for PI
3-kinase is the small GTPase Rab4. Rab4 compartmentalizes
with the Glut4 vesicle and redistributes the cytosolic fraction
upon insulin stimulation.(74,75) Overexpression of Rab4 leads
to an inhibition of insulin-stimulated Glut4 translocation,
suggesting that Rab4 is an important regulator of the mobility
of the Glut4 vesicle.(74)
PI 3-kinase-independent pathways in the
regulation of glucose transport
A potential clue towards identifying the PI 3-kinase-
independent arm of insulin action came from the idea that
signal initiation might be segregated into compartments in the
plasma membrane. One candidate for such a compartment
are caveolae, small invaginations of the plasma membrane
that are enriched in lipid-modified signaling proteins, GPI-
anchored proteins, glycolipids, sphingolipids and chole-
sterol.(76) Insulin stimulates the tyrosine phosphorylation of
caveolin, the major structural protein in caveolae.(77,78)
Investigation into this pathway revealed that it was down-
stream of the phosphorylation of another insulin receptor
substrate, the protooncogene c-Cbl.(78) The insulin-stimulated
phosphorylation of Cbl occurs only in metabolically responsive
cell lines, and not in other fibroblast lines, despite the presence
of Cbl and an active receptor.(6) These findings led us to search
for an adapter protein that might recruit Cbl to the insulin
receptor, to explain its phosphorylation only in certain cells.
The Cbl-associated protein (CAP) was identified in a two-
hybrid screen using Cbl as bait.(79) CAP contains three
carboxyl terminal SH3 domains, one of which mediates its
binding to Cbl. It is expressed predominantly in insulin
sensitive tissues and in differentiated 3T3-L1 adipocytes.
Interestingly, the CAP gene is upregulated by the insulin-
sensitizing thiazolidinediones (TZDs).(80) TZD activation of the
nuclear receptor PPARg directly activates the transcription of
CAP through a PPARg response element in the promoter of
the CAP gene.(81) Moreover, TZD-stimulated increases in
CAP expression lead to a more robust phosphorylation of Cbl
in response to insulin,(80) establishing a potential primary link
between TZD-induced insulin sensitization and insulin signal
transduction.
The CAP protein recruits Cbl to the insulin receptor in
untreated cells. Upon Cbl phosphorylation, a portion of the Cbl/
CAP complex is released from the receptor and, subsequently,
accumulates in a triton-insoluble plasma membrane domain
enriched in caveolae or lipid rafts.(78) The insulin-stimulated
phosphorylation of Cbl and its localization to the lipid raft is
independent of PI 3-kinase.
The concentration of CAP in lipid rafts appears to result
from its association with the caveolar protein flotillin.(82,83) A
dominant interfering mutant of CAP that binds to flotillin, but
not c-Cbl, interferes with this localization of Cbl to lipid rafts
(Fig. 3). Moreover, this mutant specifically blocks insulin-
stimulated Glut4 translocation and glucose uptake.(83) Once
phosphorylated, Cbl can recruit the SH2-containing adapter
protein CRKII to the lipid raft, along with the guanine nucleotide
exchange factor C3G. Although the precise target of C3G in
the lipid raft is uncertain, recent data suggest that it may
activate the rho family protein TC10.(85) This G protein is
expressed in fat and muscle, and can be acutely activated by
insulin in a CAP-dependent but PI 3-kinase-independent
manner.(84) Although the physiologically relevant effectors
that interact with TC10 are unknown, disruption of its activation
blocks insulin-stimulated glucose transport and Glut4 trans-
location.(84)
Although the targets of the PI 3-kinase and CAP pathways
are uncertain, one likelihood is that they regulate different
processes. For example, PIP3-dependent kinases may
phosphorylate proteins involved in the tethering of the Glut4
vesicle at intracellular sites, leading to the release and default
trafficking of the vesicle to the plasma membrane. On the
contrary, the CAP/TC10 pathway may regulate processes
involved in the docking and fusion of the vesicle at the plasma
membrane. One potential target of this pathway is the syntaxin
4 binding partner Snyip.(49) In the basal state, Synip inhibits the
interaction of VAMP2 in the Glut4 vesicle with the syntaxin 4/
SNAP-23 t-SNARE complex in the plasma membrane. Insulin
stimulates the disassociation of Synip from syntaxin 4,
permitting Syn4±VAMP2 binding, followed by docking and
subsequent fusion of the Glut4 vesicle with the plasma
membrane. The insulin-stimulated dissociation of Synip from
syntaxin 4 is not blocked by wortmannin.
Future prospects
Although it is clear that multiple signaling pathways are
required for the stimulation of glucose transport by insulin,
the ultimate targets of these pathways, and the biochemical
changes in these targets remain unexplored. Additionally, the
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relative importance of these pathways in different tissues, and
their role in mediating other aspects of insulin action on
metabolic enzymes, other transport processes, or gene
expression have not been evaluated. Most importantly, it will
be critical to fully evaluate the structure and functions of the
individual components of these pathways in animal models of
insulin resistance, as well as in muscle and fat from patients
with insulin resistance and type 2 diabetes.
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